Red flags / Dilution
SELLAS Life Sciences files for $150 million common stock offering
SELLAS Life Sciences Group filed a preliminary prospectus supplement under its shelf registration for a $150,000,000 offering of common stock, with an option for underwriters to buy up to an additional $22,500,000 of shares over 30 days. The stock closed at $7.47 on November 16, 2026, and the final offering price and share count are not yet stated in the filing text. A stock sale of this kind dilutes existing shareholders and can add to pressure on the share price.
“We are offering shares of our common stock.”
What the stock did
From the last close before the filing was public. Market cap now: $2.8B.
1 day
-6.3%
SPY -0.3%
5 days
Not yet
20 days
Not yet
Prospectus supplement or shelf for new shares, including at-the-market programs. Flags are a screen for filings worth reading, not advice. Read the filing before acting on it.
Other flags on SLS
| Filed | Stock | Flag | What the filing says | Mkt cap | 5 days | 20 days |
|---|---|---|---|---|---|---|
| Nov 19, 4:07 PM ET | SLS SELLAS Life Sciences Group Inc. | Dilution SevereForm 424B5 | SELLAS Life Sciences to sell 11.5 million shares at $13.00 in $150 million offering | $2.8B | - | - |